Phaseline

Targets › COMPLEMENT3

COMPLEMENT3: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Nov 2027.

Open in Phaseline: the race on COMPLEMENT3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Aura Biosciencesbelzupacap sarotalocan
Complement 3 inhibitor; intravitreal antibody targeting complement cascade
COMPLEMENT3Phase 3Choroidal MelanomaNov 2027

Conditions

Choroidal Melanoma (1)

Modalities

small molecule (1)

Companies

Aura Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.